Cannabis for Palliative Care in Cancer
NCT06266611, Phase 2, Recruiting, University of Colorado, Boulder
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Cannabis for Palliative Care in Cancer | ClinicalTrials.gov |
| NCT number | NCT06266611 | ClinicalTrials.gov |
| Status | Recruiting | ClinicalTrials.gov |
| Phases | Phase 2 | ClinicalTrials.gov |
| Enrollment | 185 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | University of Colorado, Boulder | ClinicalTrials.gov |
| Conditions | Sleep, Anxiety, Depression, Pain | ClinicalTrials.gov |
| Interventions | fsCBD Cannabidiol, Placebo, bsCBD Cannabidiol | ClinicalTrials.gov |
| First posted | 2024-02-20 | ClinicalTrials.gov |
| Last updated | 2025-08-01 | ClinicalTrials.gov |
Registered outcomes 23
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Pain Interference | Baseline, 4 weeks, 8 weeks | PROMIS (Patient-Reported Outcomes Measurement Information System) Pain Interference. Total scores are between 8 and 40, with higher scores meaning more pain interference. | ClinicalTrials.gov |
| Primary | Pain Intensity | Baseline, 4 weeks, 8 weeks | PROMIS (Patient-Reported Outcomes Measurement Information System) Pain Intensity (7-day). Scores are between 0-10, with 0 being no pain and 10 being the worst imaginable pain. | ClinicalTrials.gov |
| Primary | Pain Inventory | Baseline, 4 weeks, 8 weeks | Brief Pain Inventory (BPI) survey. Measures pain levels, pain interference, and relief from medication, and includes diagrams for labeling pain. For pain levels, various questions ask participants to rate pain on a scale of 0-10, 0 being no pain and 10 being pain as bad as you can imagine. For questions about pain interference, each question is on a scale of 0-10, where 0 does not interfere and 10 completely interferes. BPI is scored as an average of each subsection, where a higher average suggests greater severity of pain/more interference. | ClinicalTrials.gov |
| Primary | Sleep Disturbance | Baseline, 4 weeks, 8 weeks | PROMIS (Patient-Reported Outcomes Measurement Information System) Sleep Disturbance 4a. Scores are separated between the first question (sleep quality) and the remaining 7 questions. For the first question, scores are between 1 and 5, with 1 being very poor sleep quality and 5 being very good sleep quality. The remaining 7 questions are scored individually on a scale of 1--5; for some questions, higher scores mean less disturbance, and for others, a higher score means more disturbance. | ClinicalTrials.gov |
| Primary | Sleep-Related Impairment | Baseline, 4 weeks, 8 weeks | PROMIS (Patient-Reported Outcomes Measurement Information System) Sleep-Related Impairment 4a. Scores are between 4 and 20, with higher scores indicating more sleep-related impairment | ClinicalTrials.gov |
| Primary | Depression/Anxiety | Baseline, 4 weeks, 8 weeks | Depression Anxiety Stress Scale - 21 Item (DASS-21). Scores are between 0 and 63, with higher scores indicating more negative emotional states. | ClinicalTrials.gov |
| Primary | Fatigue | Baseline, 4 weeks, 8 weeks | PROMIS (Patient-Reported Outcomes Measurement Information System) Fatigue 4a. Scores range from 4-20, with higher scores indicating more fatigue. | ClinicalTrials.gov |
| Primary | Health Related Quality of Life | Baseline, 4 weeks, 8 weeks | Health Related Quality of Life Short Form 12 (SF-12). Scores range from 0-100 with higher scores indicating better health. | ClinicalTrials.gov |
| Primary | FACT-Cog Cognitive Function | Baseline, 4 weeks, 8 weeks | Functional Assessment of Cognitive Function - Cognitive (FACT-Cog). Scores are transformed such that scores range from 0-132 and higher scores indicate a better quality of life/cognitive function. | ClinicalTrials.gov |
| Primary | Stroop Task Test of Cognitive Function | Baseline, 4 weeks, 8 weeks | Stroop Task | ClinicalTrials.gov |
| Primary | DSST Test of Cognitive Function | Baseline, 4 weeks, 8 weeks | Digit Symbol Substitution Task (DSST) | ClinicalTrials.gov |
| Primary | Conners Test of Cognitive Function | Baseline, 4 weeks, 8 weeks | Conners Continuous Performance Test - Version 3 (CPT-3) | ClinicalTrials.gov |
| Primary | Plasma Cannabinoids | Baseline, 4 weeks, 8 weeks | Plasma cannabinoid levels in participants will be measured from biological samples. | ClinicalTrials.gov |
| Primary | PROMIS Pain Intensity (Right Now) | 4 weeks | PROMIS (Patient-Reported Outcomes Measurement Information System) Pain Intensity (Right Now). Scores are between 0-10, with 0 being no pain and 10 being the worst imaginable pain. | ClinicalTrials.gov |
| Primary | Drug Effects | 4 weeks | Drug Effects Questionnaire (DEQ). Six questions about drug effects with possible answers of "not at all", "somewhat", and "extremely", where higher scores indicate higher drug effects. | ClinicalTrials.gov |
| Primary | ARCI-Marijuana Scale | 4 weeks | Addiction Research Center Inventory - Marijuana Scale (ARCI-M). 12 True or false questions where more "true" answers indicate higher drug effects. | ClinicalTrials.gov |
| Primary | Drug Effects - Mood | 4 weeks | Profile of Mood States (POMS). Scores are between 28-140, with higher scores indicating higher drug effects. | ClinicalTrials.gov |
| Primary | Drug Effects - Blood Cannabinoids | 4 weeks | Acute plasma cannabinoid levels in participants will be measured from blood samples pre-drug administration, on-hour post drug administration, and 2-hours post drug administration at week 4 appointment. | ClinicalTrials.gov |
| Secondary | Polypharmacy for Pain | Baseline, 4 weeks, 8 weeks | Use of pain medications | ClinicalTrials.gov |
| Secondary | Polypharmacy for Psychiatric Rx | Baseline, 4 weeks, 8 weeks | Use of psychiatric medications | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 3
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Continuous Performance Test | Primary outcome | ConductCognition |
| Stroop Color-Word Test | Primary outcome | ConductCognition |
| Symbol Coding | Primary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)